Statement Of Cash Flows [Abstract]

Hyloris Pharmaceuticals SA - Filing #3166143

Concept	2023-01-01 to 2023-12-31	As at 2023-12-31	As at 2022-12-31	2022-01-01 to 2022-12-31	As at 2021-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Cash flows from (used in) operations	12,756,000 EUR	—	—	12,679,000 EUR	—
Interest paid, classified as operating activities	52,000 EUR	—	—	7,000 EUR	—
Income taxes paid (refund), classified as operating activities	- EUR	—	—	349,000 EUR	—
Cash flows from (used in) operating activities	12,808,000 EUR	—	—	13,020,000 EUR	—
Cash flows from (used in) investing activities [abstract]
Other cash payments to acquire equity or debt instruments of other entities, classified as investing activities	0 EUR	—	—	500,000 EUR	—
Purchase of property, plant and equipment, classified as investing activities	298,000 EUR	—	—	101,000 EUR	—
Purchase of intangible assets, classified as investing activities	452,000 EUR	—	—	638,000 EUR	—
Cash advances and loans made to other parties, classified as investing activities	- EUR	—	—	655,000 EUR	—
Interest received, classified as investing activities	638,000 EUR	—	—	—	—
Cash flows from (used in) investing activities	9,889,000 EUR	—	—	11,373,000 EUR	—
Cash flows from (used in) financing activities [abstract]
Proceeds from issuing shares	- EUR	—	—	14,337,000 EUR	—
Proceeds from borrowings, classified as financing activities	51,000 EUR	—	—	- EUR	—
Repayments of borrowings, classified as financing activities	- EUR	—	—	- EUR	—
Payments of lease liabilities, classified as financing activities	170,000 EUR	—	—	79,000 EUR	—
Interest paid, classified as financing activities	12,000 EUR	—	—	1,877,000 EUR	—
Cash flows from (used in) financing activities	131,000 EUR	—	—	7,838,000 EUR	—
Increase (decrease) in cash and cash equivalents after effect of exchange rate changes	3,051,000 EUR	—	—	16,555,000 EUR	—
Cash and cash equivalents	—	30,406,000 EUR	33,457,000 EUR	—	50,012,000 EUR